Lunch Symposia

Attendance to lunchtime symposia are included in full meeting registration fee. Please nominate your interest upon registration.

Lunchtime symposia will be run at the Adelaide Convention Centre.

Thursday 11 October

This session is proudly sponsored by:

 1330-1415

Individualised Lung-Protective Ventilation

Dr Mirko Belliato

Application of lung-protective ventilation to prevent the occurrence of VILI is currently based on low tidal volume/plateau pressure and moderate-to-high PEEP. But can the same lung-protective strategy be applied to all mechanically ventilated patients or is a more individualised approach needed?


Individualised protective ventilation that includes adjusting VT according to the size of the lung's aerated portion ("baby" lung) rather than the assumed "healthy" lung may improve lung protection. In addition, assessing recruitability in patients could help avoid the harmful effects of lung over-distension, as a recruitment strategy may only improve outcomes when applied in patients with high recruitment potential.
 

Saturday 13 October

This session is proudly sponsored by:

1320-1405

Nasal High Flow and NIV: The Pendulum Shift?

Prof. François Stéphan, Head of Intensive Care, Marie Lannelongue Hospital, Paris, France

Nasal high flow (NHF) therapy has the potential to support patients across a broad range of acuities and presentations. In this evidence-based symposium, the use of NHF therapy in the setting of non-invasive respiratory support will be discussed.

Target Audience

Medical, Nursing, and Allied Health staff involved in the assessment and treatment of patients with acute respiratory failure

Learning Objectives

  • Discuss the indications for use of NHF therapy both in the ICU and beyond
  • Identify the current evidence for NHF therapy including its mechanisms of action
  • Discuss the evidence supporting the use of NHF as an alternative to NIV to patients with acute respiratory failure
  • Discuss the evidence supporting the use of NHF to improve success of NIV treatment
  • Evaluate the emerging and clinically significant applications for NHF therapy